Pharmaceutical Industry discussion, review, analysis, news and information.

At the recommended dosage, Botox Cosmetic (botulinum toxin type A) also known as VISTABEL or VISTABEX in Europe proved to be more efficient and tolerable in treating moderate to severe glabellar lines (the vertical frowns between the brows) compared to DYSPORT, a brand of botulinum toxin type A that is available in Europe but not yet approved for use in the U.S. The study presented at the American Academy of Dermatology’s Annual Winter Meeting in San Francisco showed that with Botox Cosmetic, patients are more satisfied and the effect is more lasting.

 

"There are important biological, pharmacological and clinical differences between botulinum toxin formulations and they are not interchangeable at a single dosing ratio," said Nicholas Lowe, M.D., FRCP, principal investigator for the study. "This study suggests that Dysport(R) may need to be used at higher doses than the currently recommended dose of 50 units for the treatment of glabellar lines to achieve duration of effect and patient satisfaction comparable to BOTOX(R) Cosmetic."